成人膀胱癌机器人辅助与开放根治性膀胱切除术的比较
该系统综述纳入5项随机对照试验共541例成人膀胱癌患者,比较机器人辅助与开放根治性膀胱切除术的效果差异。结果显示两者在复发时间、主要并发症、生活质量和手术切缘阳性率方面可能相似,机器人辅助可能减少输血需求并略微缩短住院时间,但证据确定性多为低至极低。
要点
- 机器人辅助与开放根治性膀胱切除术的复发时间可能相似(HR 1.05,95%CI 0.77-1.43,低确定性证据)。
- 机器人辅助可能大幅减少输血需求(RR 0.58,95%CI 0.43-0.80,中等确定性证据)。
- 机器人辅助可能略微缩短住院时间(均差-0.67天,95%CI -1.22至-0.12,低确定性证据)。
核心结论
- 机器人辅助与开放根治性膀胱切除术在复发时间、主要并发症率、生活质量和手术切缘阳性率方面可能相似(均为低确定性证据)。
- 机器人辅助是否减少次要并发症非常不确定(极低确定性证据),但可能大幅降低输血风险(中等确定性证据)并可能略微缩短住院时间(低确定性证据)。
- 无法进行预先计划的亚组分析来评估患者年龄、病理分期、体型或外科医生经验对结果的影响。
- 本综述未涉及成本效益问题。
研究设计与样本
- 系统综述与荟萃分析,检索截至2018年7月1日,纳入5项随机对照试验共541例成人膀胱癌患者,其中开放根治性膀胱切除术组270例,机器人辅助根治性膀胱切除术组271例。
- 检索数据库包括Cochrane对照试验中心注册库、MEDLINE(1999年至2018年7月)、PubMed Embase(1999年至2018年7月)、Web of Science(1999年至2018年7月)、英国癌症研究(www.cancerresearchuk.org/)和癌症研究所(www.icr.ac.uk/),以及临床试验注册平台。
- 两位作者使用Cochrane偏倚风险工具评估偏倚风险,并根据GRADE评级证据质量,使用Review Manager 5分析数据。
主要发现
- 机器人辅助与开放手术的复发时间可能相似(风险比1.05,95%CI 0.77至1.43;2项试验,低确定性证据),5年随访时相当于每1000例参与者增加16例复发(95%CI减少79例至增加123例),开放手术组每1000例参与者有431例复发。
- 机器人辅助与开放手术的主要并发症率可能相似(风险比1.06,95%CI 0.76至1.48;5项试验,低确定性证据),相当于每1000例参与者增加11例主要并发症(95%CI减少44例至增加89例)。
- 机器人辅助是否减少次要并发症非常不确定(极低确定性证据)。
- 机器人辅助可能大幅减少输血需求(风险比0.58,95%CI 0.43至0.80;2项试验,中等确定性证据),基于开放手术组每1000例参与者460例输血,相当于每1000例参与者减少193例输血(95%CI减少262例至减少92例)。
- 机器人辅助可能略微缩短住院时间(均差-0.67,95%CI -1.22至-0.12;5项试验,低确定性证据),与开放手术可能生活质量相似(标准化均差0.08,95%CI -0.32至0.16;3项试验,低确定性证据),手术切缘阳性率可能相似(风险比1.16,95%CI 0.56至2.40;5项试验,低确定性证据),基于开放手术组每1000例参与者48例切缘阳性,相当于每1000例参与者增加8例(95%CI减少21例至增加67例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因研究局限性和不精确性,复发时间、主要并发症、住院时间和生活质量的证据确定性被降级。
- 因研究局限性和极严重的不精确性,次要并发症的证据确定性被降级。
- 因研究局限性,输血需求的证据确定性被降级。
- 无法进行预先计划的亚组分析来评估患者年龄、病理分期、体型或外科医生经验对结果的影响。
- 本综述未涉及成本效益问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been suggested that, in comparison with open radical cystectomy (ORC), robot-assisted radical cystectomy (RARC) results in less blood loss, shorter convalescence and fewer complications, with equivalent short-term oncological and functional outcomes; however, uncertainty remains as to the magnitude of these benefits. OBJECTIVES: To assess the effects of RARC vs ORC in adults with bladder cancer. SEARCH METHODS: We conducted a comprehensive search, with no restrictions on language of publication or publication status, for randomized controlled trials (RCTs) that compared RARC with ORC. The date of the last search was 1 July 2018. Databases searched included the Cochrane Central Register of Controlled Trials, MEDLINE (1999 to July 2018), PubMed Embase (1999 to July 2018), Web of Science (1999 to July 2018), Cancer Research UK (www.cancerresearchuk.org/), and the Institute of Cancer Research (www.icr.ac.uk/). We also searched the following trial registers: ClinicalTrials.gov (clinicaltrials.gov/); BioMed Central International Standard Randomized Controlled Trials Number (ISRCTN) Registry (www.isrctn.com); and the World Health Organization International Clinical Trials Registry Platform. The review was based on a published protocol. Primary outcomes of the review were recurrence-free survival and major postoperative complications (Clavien grade III to V). Secondary outcomes were minor postoperative complications (Clavien grades I and II), transfusion requirement, length of hospital stay (days), quality of life, and positive surgical margins (%). Three review authors independently assessed relevant titles and abstracts of records identified by the literature search to determine which studies should be assessed further. Two review authors assessed risk of bias using the Cochrane risk-of-bias tool and rated the quality of evidence according to GRADE. We used Review Manager 5 to analyse the data. RESULTS: We included in the review five RCTs comprising a total of 541 participants. Total numbers of participants included in the ORC and RARC cohorts were 270 and 271, respectively. We found that RARC and ORC may result in a similar time to recurrence (hazard ratio 1.05, 95% confidence interval [CI] 0.77 to 1.43; two trials, low-certainty evidence). In absolute terms at 5 years of follow-up, this corresponds to 16 more recurrences per 1000 participants (95% CI 79 fewer to 123 more) with 431 recurrences per 1000 participants for ORC. We downgraded the certainty of evidence because of study limitations and imprecision. RARC and ORC may result in similar rates of major complications (risk ratio [RR] 1.06, 95% CI 0.76 to 1.48; five trials, low-certainty evidence). This corresponds to 11 more major complications per 1000 participants (95% CI 44 fewer to 89 more). We downgraded the certainty of evidence because of study limitations and imprecision. We were very uncertain whether RARC reduces minor complications (very-low-certainty evidence). We downgraded the certainty of evidence because of study limitations and very serious imprecision. RARC probably results in substantially fewer transfusions than ORC (RR 0.58, 95% CI 0.43 to 0.80; two trials, moderate-certainty evidence). This corresponds to 193 fewer transfusions per 1000 participants (95% CI 262 fewer to 92 fewer) based on 460 transfusion per 1000 participants for ORC. We downgraded the certainty of evidence because of study limitations. RARC may result in a slightly shorter hospital stay than ORC (mean difference -0.67, 95% CI -1.22 to -0.12; five trials, low-certainty evidence). We downgraded the certainty of evidence because of study limitations and imprecision. RARC and ORC may result in a similar quality of life (standardized mean difference 0.08, 95% CI 0.32 lower to 0.16 higher; three trials, low-certainty evidence). We downgraded the certainty of evidence because of study limitations and imprecision. RARC and ORC may result in similar positive surgical margin rates (RR 1.16, 95% CI 0.56 to 2.40; five trials, low-certainty evidence). This corresponds to eight more (95% CI 21 fewer to 67 more) positive surgical margins per 1000 participants, based on 48 positive surgical margins per 1000 participants for ORC. We downgraded the certainty of evidence because of study limitations and imprecision. CONCLUSIONS: We conclude that RARC and ORC may have similar outcomes with regard to time to recurrence, rates of major complications, quality of life, and positive surgical margin rates (all low-certainty evidence). We are very uncertain whether the robotic approach reduces rates of minor complications (very-low-certainty evidence), although it probably reduces the risk of blood transfusions substantially (moderate-certainty evidence) and may reduce hospital stay slightly (low-certainty evidence). We were unable to conduct any of the preplanned subgroup analyses to assess the impact of patient age, pathological stage, body habitus, or surgeon expertise on outcomes. This review did not address issues of cost-effectiveness.
引用
- Rai BP, Bondad J, Vasdev N, et al. Robot-assisted vs open radical cystectomy for bladder cancer in adults. BJU Int. 2020. PMID: 31309688. doi:10.1111/bju.14870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。